3rd Cell Therapy for Autoimmune Disease Summit
December 2-4, 2025 | Philadelphia, PA
Drive Transformative Therapeutic & Clinical Advances in Diverse Autoimmune Cell Therapies with Demonstrated Safety, Durable Efficacy & Improved Patient Accessibility to Redefine the Long-Term Management of Autoimmune Diseases
The 3rd Cell Therapy for Autoimmune Disease Summit arrives at a pivotal time, with autoimmune therapies set to shape the next wave of cell therapy innovation. As the sole meeting dedicated to advances in CAR-T, Treg, NK, and in vivo approaches, it offers a unique chance to gain comprehensive insights and successfully navigate the fast-evolving path to market.
16th World ADC London Summit
February 23 – 26, 2026 | London, UK
At World ADC London, innovation leads the way as 2026 spotlights breakthrough ADC advances, uniting global expertise to transform precision cancer treatment and elevate therapeutic impact across Europe.
World ADC London 2026 unites more than 800 senior European ADC leaders from biopharma, clinical practice, service providers, investment, and regulatory bodies to shape the next era of ADC development. This year’s programme focuses on securing ADCs as standard-of-care therapies by advancing novel payload mechanisms to overcome Topo1 resistance, improving translation of safe and effective ADCs into the clinic, and strengthening manufacturing capabilities. Join the community driving ADC innovation.
10th CAR-TCR Summit Europe
February 24 – 26, 2026 | London, UK
Bringing together leaders from across Europe and Asia, CAR-TCR Europe accelerates the development and delivery of transformative CAR-TCR therapies, advancing global collaboration to ensure patients benefit from the next generation of cellular immunotherapies.
The 10th CAR-TCR Summit Europe, held 24–26 February 2026 in London, brings together leading experts from Europe and Asia to accelerate the development of next-generation CAR and TCR cell therapies. Starting with strategic bootcamps on regulatory pathways and funding, the conference spans R&D, clinical data, and manufacturing tracks — covering novel receptor design, scale-up, automation, in-vivo cell engineering, and strategies to boost patient access and commercial viability.
6th TPD & Induced Proximity Summit Europe
March 10 – 12, 2026 | London, UK
Advancing PROTACs, molecular glues, and next-generation proximity-based therapeutics with enhanced safety and drug-like properties to drive clinical translation and unlock previously undruggable targets across oncology and wider disease areas.
The 6th TPD & Induced Proximity Summit Europe is Europe’s definitive meeting dedicated to proximity-based drug discovery. Showcasing innovations spanning PROTACs, molecular glues, stabilizers, and extracellular degraders, it highlights therapeutic advances across oncology, neurodegeneration, immunology, and rare diseases. Taking place in London in March 2026, the summit convenes over 80 CxOs, directors, senior scientists, and investors to drive the progression of proximity-based therapeutics from early discovery through to clinical translation.
5th Novel Conjugates Summit
March 17 – 19, 2026 | Boston, MA
Showcasing cutting-edge targeting formats and payload innovations designed to improve delivery, overcome resistance, and broaden the therapeutic potential of next-generation treatments across challenging disease areas.
Novel conjugates are rapidly emerging as one of the most competitive frontiers in precision oncology. With companies advancing beyond traditional ADCs, the focus is shifting toward new payload mechanisms and differentiated targeting formats to overcome resistance, widen therapeutic windows, address ADC-refractory cancers, and expand into non-oncology indications. The 5th Novel Conjugates Summit is the only industry meeting dedicated to offering deep insight into the most promising approaches, their advantages, and the future direction of this fast-evolving field.
8th Treg-Directed Therapies Summit
March 24 – 26, 2026 | Boston, MA
Advancing modulator and Treg cell therapies to accelerate clinical translation, redefine immune tolerance, and deliver transformative treatments for autoimmune, inflammatory, and neurodegenerative diseases.
With growing momentum—highlighted by Nobel recognition, Nektar Therapeutics’ clinical progress, and ORCA-T’s potential as the first FDA-approved Treg therapy—Treg therapeutics are entering a pivotal era. The 8th Treg-Directed Therapies Summit gathers leading experts from Quell Therapeutics, Nektar, Sanofi, Yale, and others to address challenges in cell targeting, mechanisms of action, cytokine biology, indication prioritization, GMP and regulatory pathways, clinical trial design, and validated efficacy endpoints to advance Treg therapies toward broader clinical success.
Neuroscience Innovation Pharma Partnering Summit
April 28-29 , 2026 | Boston, MA
Advance collaboration and partnerships across neurology and psychiatry to de-risk development, validate emerging technologies, and achieve improved biodistribution of safe, effective molecules targeting the central nervous system.
The Neuroscience Innovation Pharma Partnering Summit brings together pharma, biotech and investor leaders to accelerate collaboration in neurology and psychiatry. With a focus on CNS drug delivery, modality innovation and efficient partnering, the summit enables pre-scheduled one-on-one meetings and curated networking — including speed-matchmaking — to validate technologies, de-risk pipelines, and secure strategic alliances. It’s a targeted, high-impact forum to help safe, effective CNS therapies reach patients faster.
Search